Abstract:Potential conflict of interest: Nothing to report. To the Editor: We read with great interest the recent work of Boursier et al., who investigated the relationship between gut dysbiosis and the severity of nonalcoholic fatty liver disease (NAFLD).1 With a well‐characterized and well‐balanced population of biopsy‐proven NAFLD patients, the diversity and composition of gut microbiota were investigated using the MiSeq sequencing platform. Several key functional bacterial phylotypes such as Bacteroides, Prevotella, and Ruminococcus were identified to be associated with the severity of NAFLD. Besides the classical predictors, the present data indicated that the gut microbiota would provide new insights on the diagnosis of NAFLD. For gut microbiomic analysis, both the diversity indices and taxonomic composition were used to define the status of the gut ecosystem. Only alterations of the taxonomic composition, especially those abundant genera, could not determine the status of the gut ecosystem as dysbiosis accurately. Other indices such as α‐diversity, β‐diversity, and Good's coverage would provide more meaningful information for the alterations of the overall structure and composition of gut microbiota. However, the important indices of diversity, such as Shannon and Simpson, seemed to be ignored in the Boursier et al. study as they could stress considerable variation in response to changes in the richness and evenness of the gut microbiota.2 In addition, the Firmicutes/Bacteroidetes ratio was considered to be representative of health status and might be considered an important marker to evaluate eubiosis or dysbiosis of the gut. Without healthy control, the diagnosis of gut dysbiosis might be arbitrary in these patients with NAFLD. For microbiomic biomarker discovery and explanation, the alterations of gut microbiota also could be analyzed by linear discriminant analysis effect size, which would emphasize both statistical significance and biological relevance. Linear discriminant analysis effect size could identify not only the differences of abundant bacteria but also those nonabundant ones. As one of the microbiota‐driven diseases, NAFLD could not just alter those abundant bacteria.4 In addition, the sensitivity and specificity of the microbiota‐targeted biomarkers should be provided in order to facilitate the clinical application for NAFLD noninvasive discrimination. Receiver‐operating characteristic curves could be used to identify the best cutoff levels for these bacteria, while the respective areas under the curve could represent the diagnostic accuracy for NAFLD. With larger scales of NAFLD patients in different stages, the diagnostic value of these genera with best cutoff levels could be verified. Furthermore, the endotoxin‐induced inflammation was not correlated with those altered genera, which would clarify their relationships in the microbiota‐gut‐liver axis. In conclusion, the study provided new insights; however, the microbiota evaluation and the diagnostic accuracy were still limited. Without a comprehensive understanding of the overall structure and composition of the gut microbiota and the diagnostic value of the key functional bacteria, it was difficult to decipher the real roles of the gut microbiota in the development of NAFLD.

Prevotella copri Promotes Lipopolysaccharide Biosynthesis and Network Instability in the Prevotella Enterotype

Gut microbiota signatures and lipids metabolism profiles by exposure to polyene phosphatidylcholine.

The Association Between Prevotella copri and Advanced Fibrosis in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease

Integrative analysis of gut microbiota and fecal metabolites in metabolic associated fatty liver disease patients

Shifts in the Bacterial Community of Supragingival Plaque Associated With Metabolic-Associated Fatty Liver Disease

Shifts in the bacterial community of supragingival plaque related to metabolic associated fatty liver disease

Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease

Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-Alcoholic Fatty Liver Disease

Advances in the study of oral microbiota and metabolism associated fatty liver disease: a systematic review

Mapping the Human Oral and Gut Fungal Microbiota in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease.

An Integrated Analysis of the Role of Gut Microbiome-Associated Metabolites in the Detection of MASH-Related Cirrhosis

Predictive Roles of Gut Dysbiosis on the Severity of Nonalcoholic Fatty Liver Disease

Prevotella copri increases fat accumulation in pigs fed with formula diets

Ecological Shifts of Salivary Microbiota Associated with Metabolic-Associated Fatty Liver Disease

Abundance of Prevotella copri in gut microbiota is inversely related to a healthy diet in patients with type 2 diabetes

Characterization of microbiome and metabolite analyses in patients with metabolic associated fatty liver disease and type II diabetes mellitus

Roles of gut microbes in metabolic-associated fatty liver disease

Effects of Prevotella copri on insulin, gut microbiota and bile acids

Polysaccharides: The Potential Prebiotics for Metabolic Associated Fatty Liver Disease (MAFLD)

P090 Prevotella copri promotes colitis in mice by reducing expression of ATF4 and disturbing the gut microbiota

Associations of the gut microbiome with hepatic adiposity in the Multiethnic Cohort Adiposity Phenotype Study